Liver cirrhosis treatment market analysis by treatment and end user - forecast to 2030. Market Research Future estimated that the global liver cirrhosis treatment market size is set to grow at highest CAGR of 10.90% and attain a valuation of 14803.26 million during the forecast period, 2022-2030.
The liver cirrhosis treatment market is witnessing significant growth globally, fueled by the escalating prevalence of liver cirrhosis, a chronic condition characterized by liver scarring and impaired function. This rise is attributed to factors such as alcohol abuse, viral hepatitis infections, and the increasing incidence of non-alcoholic fatty liver disease (NAFLD). The market's expansion is further propelled by a growing awareness of advanced treatment options and the adoption of improved diagnostic techniques.
Current treatment approaches for liver cirrhosis encompass lifestyle modifications, pharmacological interventions, and, in severe cases, liver transplantation. Therapies targeting the underlying causes, such as antiviral medications for hepatitis infections and lifestyle interventions for NAFLD, are gaining prominence. Additionally, ongoing research and development efforts focus on innovative treatments to halt or reverse liver fibrosis, addressing a critical unmet need in the market.
Geographically, North America and Europe lead the Liver Cirrhosis Treatment Market, driven by a higher prevalence of contributing factors and well-established healthcare infrastructure. The Asia-Pacific region is anticipated to witness substantial growth due to the increasing burden of liver cirrhosis and improving access to healthcare.
The market is characterized by strategic collaborations, research partnerships, and investments in novel therapeutic approaches. As advancements in liver cirrhosis research continue, the market is poised for sustained growth, offering hope for improved outcomes and quality of life for individuals affected by this serious condition.
Market Participants
The global liver cirrhosis treatment market is currently dominated by several market players. Key players participate in product launches and strategic partnerships to strengthen their market positions. These market participants include Pfizer, Inc., Novartis AG, Merck Co., Inc., Takeda Pharmaceutical Company Limited, Hoffmann-La Roche Ltd, AstraZeneca, Promethean, Gilead Sciences, Inc., Sanofi, Bayer AG, Shionogi Inc., and others.
Market Segmentation
The global liver cirrhosis treatment market size is segmented with antibiotics, immunosuppressant’s, etc.
The antibiotic segment is expected to dominate most of the market, with antibiotics being the most recommended type of drug for patients with liver cirrhosis due to the high risk of infections.
The immunosuppressant segment is expected to grow more rapidly due to the increasing number of liver transplants. Immunosuppressant drugs are prescription drugs for patients who have had a liver transplant to reduce the risk of organ rejection.
Other liver cirrhosis treatment options include reduce medications to reduce blood pressure, ammonia levels, and antihypertensive drugs.
The end-user market is subdivided into hospitals and clinics, research institutes and academics, etc. The hospital and clinic segment is expected to hold the largest share of the market, as these are the most important treatment centers for the patient. Research institutes and academics are conducting research to develop new treatment options for cirrhosis of the liver. Other end-users are home care facilities and elderly-specific treatment centers.
Regional Outlook
The Americas are the largest regional market. The prevalence of cirrhosis of the liver is high in America. In October 2017, about 88,000 people died of liver disease and alcohol-related cirrhosis in the United States. In addition, the health infrastructure of North and South America is being developed, contributing to market growth. In addition, leading pharmaceutical companies such as Pfizer Inc. and Gilead Sciences, Inc. are headquartered in the United States, which positively contributes to the growth of the North and South American treatment market for cirrhosis. .
A growing geriatric population and increasing investments in research and development for the development of innovative drugs against liver diseases should stimulate market growth in Europe. Finland and the United Kingdom have experienced an increase in liver disease mortality rates over the last 40 years. European countries such as the Germany, United Kingdom, and France have a well-developed health infrastructure that contributes to the growth of the liver cirrhosis market in Europe.
The Asia-Pacific region is experiencing an increase in the number of people suffering from cirrhosis of the liver. In addition, governmental and non-governmental organizations are implementing liver cirrhosis awareness programs, which should stimulate market growth. In addition, the geriatric population is susceptible to various liver diseases and is increasing in countries such as India, Japan and China, which has a positive effect on market growth.
As the number of people with liver cirrhosis rises, it is anticipated that the market in the Middle East and Africa would expand significantly. Due to the rapid growth of healthcare facilities in Middle Eastern nations like Saudi Arabia, Qatar, and Oman, the Middle East market is anticipated to expand more quickly than the African market.
Related Reports
For More Information Visit @ Market Research Future
